Educational Reference · Research-Use-Only
NAD+: Mechanism, Research, and Regulatory Status
A research-grade overview of NAD+ — what it is, how it works at the molecular level, what published studies have shown, and answers to the questions researchers ask most.
Last reviewed 2026-07-28
What is NAD+?
NAD+ is an obligate redox cofactor that cycles between oxidized and reduced states, accepting a hydride at the C4 position of its nicotinamide ring. In this capacity it is the principal electron carrier for glycolysis, the tricarboxylic acid cycle and fatty acid beta-oxidation, delivering reducing equivalents to complex I of the mitochondrial electron transport chain. Separately from redox cycling, NAD+ is consumed stoichiometrically as a substrate by three enzyme families that cleave the glycosidic bond and release nicotinamide: the sirtuin NAD+-dependent protein deacylases, the poly(ADP-ribose) polymerases, and the NAD+ glycohydrolases CD38 and CD157, together with SARM1 in axonal degeneration.
Because these enzymes destroy NAD+ rather than recycle it, cellular NAD+ must be continuously resynthesized. Mammalian cells regenerate NAD+ mainly through the salvage pathway, in which nicotinamide phosphoribosyltransferase — the rate-limiting step — converts nicotinamide to nicotinamide mononucleotide, which adenylyltransferases convert to NAD+ in distinct subcellular compartments. Two additional routes contribute: de novo synthesis from tryptophan via the kynurenine pathway, and the Preiss-Handler pathway from nicotinic acid.
The core preclinical hypothesis under investigation is that tissue NAD+ availability declines with age and metabolic stress, partly through increased consumption and reduced salvage activity, and that raising NAD+ with precursors restores sirtuin and mitochondrial function; the extent to which this translates to clinical benefit in humans remains unresolved, and the best-controlled trials to date have produced null results on functional endpoints.
Research highlights
What published peer-reviewed research and preclinical studies have established about NAD+:
- 01NAD+ serves a dual role as a redox coenzyme and as a consumed substrate for sirtuins, PARPs and CD38, linking cellular energy status to transcription, DNA repair and calcium signalling.
- 02Nicotinamide phosphoribosyltransferase is the rate-limiting enzyme of the mammalian salvage pathway, the dominant route of NAD+ regeneration in most tissues.
- 03Oral nicotinamide riboside 1000 mg/day for 6 weeks reliably elevated whole-blood NAD+ in healthy middle-aged and older adults, confirming that oral precursors can raise the measurable NAD+ pool (Martens 2018).
- 04NULL FINDING: in obese, insulin-resistant men, 12 weeks of nicotinamide riboside 2000 mg/day did not improve insulin sensitivity, endogenous glucose production, glucose disposal, energy expenditure, fat oxidation or body composition (Dollerup 2018).
- 05NULL FINDING: in the Martens trial, reductions in systolic blood pressure and carotid-femoral pulse wave velocity did not reach statistical significance after correction for multiple comparisons; the authors framed these as hypothesis-generating only.
- 06In aged men, 21 days of nicotinamide riboside raised the skeletal muscle NAD+ metabolome and lowered circulating inflammatory cytokines but did NOT alter mitochondrial bioenergetics, showing that elevating the NAD+ pool does not automatically produce a functional mitochondrial change (Elhassan 2019).
- 07IMPORTANT CAVEAT: most trials measure precursor-driven changes in NAD+ pools and surrogate biomarkers rather than clinical endpoints, and the human literature concerns precursors rather than NAD+ itself. Commonly asserted claims about NAD+ reversing aging in humans are not supported by the controlled trial evidence.
Published clinical and preclinical research
Chronic nicotinamide riboside supplementation in healthy middle-aged and older adults
Randomized crossover trial · 2018Nicotinamide riboside was well tolerated and significantly elevated NAD+. Reductions in systolic blood pressure and aortic pulse wave velocity were NOT statistically significant after correction for multiple comparisons.
Randomized placebo-controlled trial of nicotinamide riboside in obese men
Randomized, double-blind, placebo-controlled trial · 2018NEGATIVE. Nicotinamide riboside 1000 mg twice daily was safe but did not improve insulin sensitivity, endogenous glucose production, glucose disposal or oxidation, and had no effect on energy expenditure, fat oxidation or body composition.
Nicotinamide riboside in aged human skeletal muscle
Randomized crossover trial · 2019Elevated the muscle NAD+ metabolome and depressed circulating inflammatory cytokines, but did not alter mitochondrial bioenergetics.
Frequently asked questions about NAD+
What is NAD+?+
Beta-nicotinamide adenine dinucleotide is an endogenous dinucleotide cofactor present in every living cell. It is not a peptide and not a xenobiotic drug — it is a central metabolic coenzyme with the formula C21H27N7O14P2.
What is the difference between NAD+, NADH, NADP+ and NMN?+
NAD+ and NADH are the oxidized and reduced forms of the same redox couple. NADP+ and NADPH are the 2'-phosphorylated forms, used predominantly in reductive biosynthesis and antioxidant regeneration rather than catabolic ATP production. NMN and nicotinamide riboside are biosynthetic precursors that feed the salvage pathway upstream of NAD+, not NAD+ itself.
Why do most human studies use precursors rather than NAD+ itself?+
NAD+ is a charged dinucleotide that does not readily cross the plasma membrane intact and is subject to extracellular degradation by ectoenzymes such as CD38. Precursors that enter established salvage routes are the pharmacologically tractable approach, which is why the controlled trial literature is almost entirely about precursors rather than NAD+.
What are the stability considerations in the laboratory?+
NAD+ is hygroscopic and its aqueous solutions are labile — degradation accelerates at alkaline pH and elevated temperature, and NAD+ and NADH are differentially sensitive, with NADH comparatively acid-labile and NAD+ base-labile. Standard practice is to store the desiccated solid frozen and protected from light, prepare working solutions fresh in near-neutral buffer, and verify concentration spectrophotometrically or enzymatically before use.
What assays commonly use NAD+ as a reagent?+
NAD+ is a routine substrate or cofactor in dehydrogenase-coupled enzymatic assays read at 340 nm for NADH formation, in sirtuin deacetylase activity assays, in PARP activity and ADP-ribosylation assays, and in NAD+/NADH ratio measurements used as a readout of cellular redox state.
References & sources
Every citation below was resolved against its primary source before publication — each PMID against the PubMed record and each DOI through doi.org. Follow any link to read the paper at the publisher rather than taking our summary on trust.
- [1]Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. PMID: 33353981 DOI: 10.1038/s41580-020-00313-x
- [2]Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nature Metabolism. 2020. PMID: 32694684 DOI: 10.1038/s42255-019-0161-5
- [3]Martens CR, Denman BA, Mazzo MR, et al.. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. PMID: 29599478 DOI: 10.1038/s41467-018-03421-7
- [4]Dollerup OL, Christensen B, Svart M, et al.. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition. 2018. PMID: 29992272 DOI: 10.1093/ajcn/nqy132
- [5]Elhassan YS, Kluckova K, Fletcher RS, et al.. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019. PMID: 31412242 DOI: 10.1016/j.celrep.2019.07.043
Where this data comes from
- —Citations & trial data: PubMed (NCBI, U.S. National Library of Medicine), Crossref and ClinicalTrials.gov.
- —Chemical identity: PubChem and UniProt. Where sources conflicted, the disputed value is omitted rather than guessed.
- —Regulatory status: U.S. FDA publications and, where applicable, the WADA Prohibited List. Compounding status changes frequently — verify against FDA directly before relying on it.
- —Purity, form and storage are handling and supplier conventions, not literature-derived values. Confirm against the lot-specific certificate of analysis.
Content last reviewed 2026-07-28. Compiled by Veridian Research from the primary literature. This page is an educational reference for laboratory researchers — it is not medical advice, and it describes no human use.
Regulatory status
NAD+ is an endogenous human metabolite and a widely used laboratory reagent; it is not an FDA-approved drug for any indication. Injectable or intravenous NAD+ preparations are unapproved drug products and have not been evaluated by FDA for safety or efficacy. Regulatory status differs sharply between NAD+ itself and its precursors: nicotinamide riboside has been marketed as a dietary ingredient in the US, while beta-nicotinamide mononucleotide was excluded from the dietary supplement definition by FDA under the drug-preclusion provision in 2022, a position FDA reversed in letters dated 29 September 2025. Research-grade NAD+ supplied for laboratory use is not a dietary supplement, not a drug, and is intended solely for in vitro and non-human research.
Research-Use-Only Material
Specifications and certificate of analysis
NAD+ is stocked as a research reagent. Analytical documentation — identity, purity and the lot-specific certificate of analysis — is published on the product record.
View specifications & COA →